— Akamai Technologies, Inc. (NASDAQ: AKAM) reported third-quarter 2019 earnings of $1.10 per share, vs. $1 per share expected.
— Total revenue grew 6% to $710 million, vs. $701.3 million expected.
— Security product revenue jumped 29% YoY.
— On track to achieve 30% operating margin in 2020: CEO Tom Leighton.
— AKAM shares were down 0.36% immediately following the announcement.
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated